The role of PET/CT imaging in the management of patients with non-small cell lung cancer

Konstantinos Stefanidis, Efstathia Doika

Abstract


Lung cancer represents the main cause of cancer-related deaths, at a worldwide level. Lung cancer patients need imaging guide and PET/CT scan has proven to be an important imaging tool in the diagnosis and management of lung carcinoma. Hybrid imaging has the ability to combine anatomical and functional information posing it as a gold-standard non-invasive imaging not only in the detection and staging but also in guiding the therapy treatment and monitoring the treatment response


Keywords


PET/CT, 18F-FDG, lung cancer

Full Text:

PDF

References


Mao Y, Yang D, He J, et al. Epidemiology of Lung Cancer. Surg Oncol Clin N Am. 2016;25(3):439-445. doi: 10.1016/j.soc.2016.02.001

Shankar A, Saini D, Dubey A, et al. Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward. Transl Lung Cancer Res. 2019;8(Suppl 1): S106-S121. doi:10.21037/tlcr.2019.03.03

Coleman RE, Delbeke D, Guiberteau MJ, et al. Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med. 2005;46(7):1225-1239.

Fledelius J, Khalil AA, Hjorthaug K, et al. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2’-deoxy-2’-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC). J Med Imaging Radiat Oncol. 2016;60(2):231-238. doi:10.1111/1754-9485.12427

Winther-Larsen A, Fledelius J, Sorensen BS, et al. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. Lung Cancer. 2016; 94:81-87. doi: 10.1016/j.lungcan.2016.01.024

Castello A, Toschi L, Rossi S, et al. Predictive and Prognostic Role of Metabolic Response in Patients with Stage III NSCLC Treated with Neoadjuvant Chemotherapy. Clin Lung Cancer. 2020;21(1):28-36. doi: 10.1016/j.cllc.2019.07.004

Bunyaviroch T, Coleman RE. PET evaluation of lung cancer. J Nucl Med. 2006;47(3):451-469.

Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J. 1996;9(3):410-414. doi:10.1183/09031936.96.09030410

Higashi K, Matsunari I, Ueda Y, et al. Value of whole-body FDG PET in management of lung cancer. Ann Nucl Med. 2003;17(1):1-14. doi:10.1007/BF02988253

Hochhegger B, Alves GR, Irion KL, et al. PET/CT imaging in lung cancer: indications and findings. J Bras Pneumol. 2015;41(3):264-274. doi:10.1590/S1806-37132015000004479

Vlahos I, Stefanidis K, Sheard S, et al. Lung cancer screening: nodule identification and characterization. Transl Lung Cancer Res. 2018;7(3):288-303. doi:10.21037/tlcr.2018.05.02

Leef JL 3rd, Klein JS. The solitary pulmonary nodule. Radiol Clin North Am. 2002;40(1):123-ix. doi:10.1016/s0033-8389(03)00113-1

Kim SK, Allen-Auerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007;48(2):214-220.

Martins Rde C, Almeida SA, Siciliano AA, et al. Valor do FDG [18F]-PET/TC como preditor de câncer em nódulo pulmonar solitário [Value of [18F]-FDG-PET/CT as a predictor of cancer in solitary pulmonary nodule]. J Bras Pneumol. 2008;34(7):473-480. doi:10.1590/s1806-37132008000700007

Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med. 1994;35(11):1771-1776.

Grgic A, Yüksel Y, Gröschel A, et al. Risk stratification of solitary pulmonary nodules by means of PET using (18)F-fluorodeoxyglucose and SUV quantification. Eur J Nucl Med Mol Imaging. 2010;37(6):1087-1094. doi:10.1007/s00259-010-1387-3

Vilstrup MH, Torigian DA. [18F] Fluorodeoxyglucose PET in Thoracic Malignancies. PET Clin. 2014;9(4):391-v. doi:1 0.1016/j.cpet.2014.06.002

Mosmann MP, Borba MA, de Macedo FP, et al. Solitary pulmonary nodule and (18)F-FDG PET/CT. Part 1: epidemiology, morphological evaluation and cancer probability. Radiol Bras. 2016;49(1):35-42. doi:10.1590/0100-3984.2014.0012

Zhuang H, Yu JQ, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am. 2005;43(1):121-134. doi: 10.1016/j.rcl.2004.07.005

El-Haddad G, Alavi A, Mavi A, Bural G, Zhuang H. Normal variants in [18F]-fluorodeoxyglucose PET imaging. Radiol Clin North Am. 2004;42(6):1063-viii. doi: 10.1016/j.rcl.2004.07.003

Kesner AL, Chung JH, Lind KE, et al. Validation of Software Gating: A Practical Technology for Respiratory Motion Correction in PET. Radiology. 2016;281(1):239-248. doi:10.1148/radiol.2016152105

Ettinger DS, Wood DE, Aggarwal C, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019;17(12):1464-1472. doi:10.6004/jnccn.2019.0059

National Institute for Health and Care Excellence. Lung cancer: diagnosis and management Available via nice.org.uk/guidance/ng122. Published March 28, 2019.

De Wever W, Stroobants S, Coolen J, et al. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J. 2009;33(1):201-212. doi:10.1183/09031936.00035108

De Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol. 2007;17(1):23-32. doi:10.1007/s00330-006-0284-4

Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest. 2005;128(4):2289-2297. doi:10.1378/chest.128.4.2289

Kligerman S, Digumarthy S. Staging of non-small cell lung cancer using integrated PET/CT. AJR Am J Roentgenol. 2009;193(5):1203-1211. doi:10.2214/AJR.09.3193

Broderick SR, Patterson GA. Performance of integrated positron emission tomography/computed tomography for mediastinal nodal staging in non-small cell lung carcinoma. Thorac Surg Clin. 2013;23(2):193-198. doi: 10.1016/j.thorsurg.2013.01.014

Vansteenkiste JF. Imaging in lung cancer: positron emission tomography scan. Eur Respir J Suppl. 2002; 35:49s-60s. doi:10.1183/09031936.02.00252402

Prenzel KL, Mönig SP, Sinning JM, et al. Lymph node size and metastatic infiltration in non-small cell lung cancer. Chest. 2003;123(2):463-467. doi:10.1378/chest.123.2.463

Birim O, Kappetein AP, Stijnen T, et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg. 2005;79(1):375-382. doi: 10.1016/j.athoracsur.2004.06.041

Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg. 1996;62(1):246-250. doi:10.1016/0003-4975(96)00220-2

Schrevens L, Lorent N, Dooms C, et al. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist. 2004;9(6):633-643. doi:10.1634/theoncologist.9-6-633

Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348(25):2500-2507. doi:10.1056/NEJMoa022136

Li J, Xu W, Kong F, et al. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. Surg Oncol. 2013;22(3):151-155. doi: 10.1016/j.suronc.2013.04.001

Hustinx R, Paulus P, Jacquet N, et al. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol. 1998;9(4):397-401. doi:10.1023/a:1008290027419

Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328-354. doi:10.1007/s00259-014-2961-x

Qu X, Huang X, Yan W, et al. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012;81(5):1007-1015. doi: 10.1016/j.ejrad.2011.01.126

Brink I, Schumacher T, Mix M, et al. Impact of [18F] FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31(12):1614-1620. doi:10.1007/s00259-004-1606-x

Lin M, Ambati C. The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): an analysis of 649 cases. Lung Cancer. 2012;76(3):344-349. doi: 10.1016/j.lungcan.2011.11.024

Ohno Y, Hatabu H, Takenaka D, et al. CT-guided transthoracic needle aspiration biopsy of small (< or = 20 mm) solitary pulmonary nodules. AJR Am J Roentgenol. 2003;180(6):1665-1669. doi:10.2214/ajr.180.6.1801665

Zhuang YP, Wang HY, Zhang J, et al. Diagnostic accuracy and safety of CT-guided fine needle aspiration biopsy in cavitary pulmonary lesions. Eur J Radiol. 2013;82(1):182-186. doi: 10.1016/j.ejrad.2012.09.011

Yap JT, Carney JP, Hall NC, et al. Image-guided cancer therapy using PET/CT. Cancer J. 2004;10(4):221-233. doi:10.1097/00130404-200407000-00003

Purandare NC, Kulkarni AV, Kulkarni SS, et al. 18F-FDG PET/CT-directed biopsy: does it offer incremental benefit? Nucl Med Commun. 2013;34(3):203-210. doi:10.1097/MNM.0b013e32835c5a57

Pauwels EK, Ribeiro MJ, Stoot JH, et al. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25(4):317-322. doi:10.1016/s0969-8051(97)00226-6

Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2(3):157-164. doi:10.1016/s1470-2045(00)00257-6

Hustinx R, Bénard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32(1):35-46. doi:10.1053/snuc.2002.29272

Guralnik L, Rozenberg R, Frenkel A, et al. Metabolic PET/CT-guided lung lesion biopsies: impact on diagnostic accuracy and rate of sampling error. J Nucl Med. 2015;56(4):518-522. doi:10.2967/jnumed.113.131466

Stefanidis K, Konstantellou E, Yusuf G, et al. The Evolving Landscape of Lung Cancer Surgical Resection: An Update for Radiologists with Focus on Key Chest CT Findings [published correction appears in AJR Am J Roentgenol. 2022 Feb;218(2):391]. AJR Am J Roentgenol. 2022;218(1):52-65. doi:10.2214/AJR.21.26408

Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer [published correction appears in J Thorac Cardiovasc Surg. 2007 Apr;133(4):864]. J Thorac Cardiovasc Surg. 2003;126(6):1943-1951. doi: 10.1016/j.jtcvs.2003.07.030

De Ruysscher D, Nestle U, Jeraj R, et al. PET scans in radiotherapy planning of lung cancer. Lung Cancer. 2012;75(2):141-145. doi: 10.1016/j.lungcan.2011.07.018

Zheng Y, Sun X, Wang J, et al. FDG-PET/CT imaging for tumor staging and definition of tumor volumes in radiation treatment planning in non-small cell lung cancer. Oncol Lett. 2014;7(4):1015-1020. doi:10.3892/ol.2014.1874

Nestle U, Weber W, Hentschel M, Grosu AL. Biological imaging in radiation therapy: role of positron emission tomography. Phys Med Biol. 2009;54(1):R1-R25. doi:10.1088/0031-9155/54/1/R01

Shang J, Ling X, Zhang L, et al. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2016;43(11):1945-1953. doi:10.1007/s00259-016-3420-7

Castello A, Rossi S, Lopci E. 18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art. Curr Radiopharm. 2020;13(3):228-237. doi:10.2174/1874471013666191230144821

Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003;21(14):2651-2657. doi:10.1200/JCO.2003.12.004

Liu J, Dong M, Sun X, et al. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS One. 2016;11(1): e0146195. Published 2016 Jan 4. doi: 10.1371/journal.pone.0146195

Patz EF Jr, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol. 2000;174(3):769-774. doi:10.2214/ajr.174.3.1740769

Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009;50 Suppl 1:31S-42S. doi:10.2967/jnumed.108.057216

Fledelius J, Khalil AA, Hjorthaug K, et al. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2’-deoxy-2’-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC). J Med Imaging Radiat Oncol. 2016;60(2):231-238. doi:10.1111/1754-9485.12427

Winther-Larsen A, Fledelius J, Sorensen BS, et al. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. Lung Cancer. 2016; 94:81-87. doi: 10.1016/j.lungcan.2016.01.024

Castello A, Toschi L, Rossi S, et al. Predictive and Prognostic Role of Metabolic Response in Patients with Stage III NSCLC Treated with Neoadjuvant Chemotherapy. Clin Lung Cancer. 2020;21(1):28-36. doi: 10.1016/j.cllc.2019.07.004

Burger IA, Vargas HA, Apte A, et al. PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. Nucl Med Biol. 2014;41(5):410-418. doi: 10.1016/j.nucmedbio.2014.02.006

Burger IA, Casanova R, Steiger S, et al. 18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response. J Nucl Med. 2016;57(6):849-854. doi:10.2967/jnumed.115.167684

Sheikhbahaei S, Mena E, Marcus C, et al. 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients. J Nucl Med. 2016;57(6):855-860. doi:10.2967/jnumed.115.165480




DOI: http://dx.doi.org/10.36162/hjr.v7i2.495

Refbacks

  • There are currently no refbacks.